Another Pfizer deal: Opko's once-weekly growth hormone
This article was originally published in Scrip
Executive Summary
The latest transaction in Pfizer's year-end dealmaking flurry gives the company an exclusive global license for Opko Health's once-weekly human growth hormone (hGH) candidate Lagova (hGH-CTP), which complements the big pharma's once-daily growth hormone Genotropin (somatropin).
You may also be interested in...
Ascendis Will Take On Daily Genotropin With Weekly Skytrofa
Ascendis’s growth hormone deficiency drug Skytrofa will offer a convenience advantage as a weekly injectable. But the label does not clearly delineate superiority shown in a Phase III trial.
Finance Watch: Phathom IPO Meets Pricing Goal; Cabaletta, TFF Offerings Go Low
Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.
Pfizer Grows In Rare Disease With $810m Dwarfism Company Buy
Pfizer adds to its rare disease portfolio with purchase of Therachon, a Swiss company working in achondroplasia. But whether it can catch up with Biomarin’s Phase III vosoritide is still to be seen.